Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience

1. CICHOŻ-LACH H., MICHALAK A. Liver injury in the era of COVID-19. World journal of gastroenterology 2021;27(5): 377.10.3748/wjg.v27.i5.377785684533584070Search in Google Scholar

2. DONG ZY, et al. The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 infection: a systematic review and meta-analysis. Journal of Clinical Gastroenterology 2021; 55(1): 67.10.1097/MCG.0000000000001424771364233116063Search in Google Scholar

3. KUNUTSOR SK., LAUKKANEN JA. Markers of liver injury and clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. Journal of Infection 2021; 82(1): 159–198.10.1016/j.jinf.2020.05.045725575832474033Search in Google Scholar

4. NARDO AD, et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver International 2021; 41(1): 20–32.10.1111/liv.14730775375633190346Search in Google Scholar

5. JOTHIMANI D, VENUGOPAL R, ABEDIN MF, KALIAMOORTHY I, RELA M. COVID-19 and Liver [published online ahead of print, 2020 Jun 15]. J Hepatol. 2020; S0168-8278(20)30377–9.Search in Google Scholar

6. https://www.covid-hep.net/Search in Google Scholar

7. ALQAHTANI SA, SCHATTENBERG JM. Liver injury in COVID-19: The current evidence. United European Gastroenterol J. 2020;8(5):509–519.10.1177/2050640620924157726894932450787Search in Google Scholar

8. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222–126110.1016/j.jhep.2019.02.01430926241Search in Google Scholar

9. GARRIDO I, LIBERAL R, MACEDO G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52(2):267–275. doi:10.1111/apt.1581310.1111/apt.15813727283832402090Search in Google Scholar

10. https://www.ncbi.nlm.nih.gov/books/NBK547961/ [accessed 25 July 2020]Search in Google Scholar

11. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 [accessed 25 July 2020]Search in Google Scholar

12. MARJOT, T, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hep 2021; 74(3): 567–57710.1016/j.jhep.2020.09.024753653833035628Search in Google Scholar

13. SHAO, J., et al. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hepatology international (2021): 1–11.10.1007/s12072-020-10123-0786511833548030Search in Google Scholar

14. SIKKEMA, B. J., NICOLAAS, JS., VAN WIJNGAARDEN P. No association between COVID-19 related liver injury and the course of disease: a retrospective study. Scandinavian Journal of Gastroenterology 2021; 56(1): 68–71.10.1080/00365521.2020.184248933119428Search in Google Scholar

15. YA-WEN A., et al. Liver function recovery of COVID-19 patients after discharge, a follow-up study. International journal of medical sciences 2021; 18 (1): 176.10.7150/ijms.50691Search in Google Scholar

16. HAMID S., et al. WGO Guidance for the Care of Patients with COVID-19 and Liver Disease. Journal of Clinical Gastroenterology 2021; 55 (1): 1.10.1097/MCG.0000000000001459Search in Google Scholar

17. ZHANG C, SHI L, WANG FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-430.10.1016/S2468-1253(20)30057-1Search in Google Scholar

18. https://www.who.int/publications/i/item/clinical-management-of-covid-19Search in Google Scholar